Ascendis Health Limited (JSE:ASC)
South Africa · Delayed Price · Currency is ZAR · Price in ZAc | Market Cap | 575.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 11.28M |
| Shares Out | 625.75M |
| EPS (ttm) | 0.02 |
| PE Ratio | 51.07 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,000 |
| Average Volume | 115,626 |
| Open | 92.00 |
| Previous Close | 89.00 |
| Day's Range | 92.00 - 92.00 |
| 52-Week Range | 69.00 - 104.00 |
| Beta | 0.43 |
| RSI | 63.41 |
| Earnings Date | Sep 26, 2025 |
About Ascendis Health
Ascendis Health Limited, a health and wellness company, manufactures and distributes healthcare products in South Africa. It operates through Consumer Health, and Medical Devices segments. The company offers multi-vitamin; mineral, natural, micronutrient, and nutraceutical supplements; vitamins, minerals, homeopathic, over-the-counter, complementary, alternative consumer, scripted compounding, skin, and herbal products under the Bettaway, Chela-Fer, Chela Preg, Chela Mag, Compounding Pharmacy, Junglevites, Menacal 7, Solal, Pharmachem, Reuterin... [Read more]
Financial Performance
Financial StatementsNews
Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 ...
Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 | ASND Stock News
Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating Downgrade
Ascendis (ASND) Q2 2025 Earnings Call Transcript
Ascendis wins FDA approval for growth hormone deficiency treatment
Ascendis rises after FDA priority review for genetic condition treatment
Ascendis highlights long-term efficacy of Yorvipath for hypoparathyroidism
Ascendis submits NDA for TransCon CNP for achondroplasia
Novo Nordisk, Ascendis partner to advance once-monthly obesity drug candidate
Ascendis Challenges BioMarin, But Market Response Seems Excessive
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
Ascendis Pharma A/S (NASDAQ: ASND) released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short statu...
BioMarin off 17% as Ascendis data seen as threat to Voxzogo
BioMarin Pharmaceutical (BMRN) drops 17% as Ascendis Pharma's achondroplasia candidate shows promising results, posing potential competition for Voxzogo. Read ore here.